Canada markets closed

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6400+0.0350 (+2.18%)
At close: 04:00PM EDT
1.6400 0.00 (0.00%)
After hours: 04:00PM EDT

Iterum Therapeutics plc

Fitzwilliam Court
1st Floor Leeson Close
Dublin D02 YW24
353 1 669 4820

Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Corey N. FishmanPresident, CEO & Director1.3MN/A1965
Ms. Judith M. MatthewsChief Financial Officer747.77kN/A1970
Dr. Michael W. Dunne M.D.Strategic Advisor & Director115kN/A1960
Mr. Tom Loughman Ph.D.Senior Vice President of Technical OperationsN/AN/AN/A
Ms. Louise BarrettSenior Vice President of Legal Affairs & SecretaryN/AN/AN/A
Dr. Steven I. Aronin M.D.Senior VP & Head of Clinical DevelopmentN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Corporate Governance

Iterum Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.